Cover Image

The CCR5-agonist maraviroc reverses HIV latency, results from ex vivo studies and a randomized placebo controlled clinical trial

Saved in:

Bibliographic Details
Main Authors:	J. Symons (Author), S.F.L. van Lelyveld (Author), W. de Spiegelaere (Author), A.M.J. Wensing (Author), J. Drylewicz (Author), A.I.M. Hoepelman (Author), P.U. Cameron (Author), H. Lu (Author), T. Mota (Author), A.I. Dantanarayana (Author), L. Vandekerckhove (Author), S.R. Lewin (Author), K. Tesselaar (Author), M. Nijhuis (Author)
Format:	Book
Published:	Elsevier, 2017-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

PP 1.7 - 00051 Continuous decline of intact proviral DNA after two decades of antiretroviral therapy
by: M. Nühn, et al.
Published: (2022)

Maraviroc reactivates HIV with a potency similar to that of other latency reversing drugs without inducing toxicity in CD8 T cells
by: S. Moreno, et al.
Published: (2019)

CCR5 Antagonist Maraviroc Inhibits Acute Exacerbation of Lung Inflammation Triggered by Influenza Virus in Cigarette Smoke-Exposed Mice
by: Maximiliano Ruben Ferrero, et al.
Published: (2021)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
by: Gonzalez-Serna A, et al.
Published: (2016)

OA3-3 Anti-PD-1 disrupts HIV latency in non-proliferating but not in proliferating T cells
by: R.M. Van der Sluis, et al.
Published: (2017)

Integration site analysis of latently infected cell lines: evidence of ongoing replication
by: J. Symons, et al.
Published: (2015)

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal
by: T.M. Mota, et al.
Published: (2016)

Co-culture of T-cells with dendritic cells facilitates HIV latency in proliferating CD4+ T-cells: implications for the establishment and reversal of latency
by: N. Kumar, et al.
Published: (2015)

OA3-5 LB Effect of vorinostat, hydroxychloroquine and maraviroc combination therapy on viremia following treatment interruption in individuals initiating ART during acute HIV infection
by: E. Kroon, et al.
Published: (2016)

Maraviroc: a review of its use in HIV infection and beyond
by: Woollard SM, et al.
Published: (2015)

P1 Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro latency models
by: Pawel Bonczkowski, et al.
Published: (2016)

The transcriptional program governed by RORγt favors HIV-1 replication in CCR4+CCR6+ Th17 cells
by: V.S. Wacleche, et al.
Published: (2015)

Development and evaluation of mucoadhesive bigel containing tenofovir and maraviroc for HIV prophylaxis
by: Margaret O. Ilomuanya, et al.
Published: (2020)

PP 1.34 - 00170 Intestinal endothelial cells substantially increase HIV infection and latency in resting and activated CD4+ T cells, particularly affecting CCR6+ Th17 subpopulation
by: J. Eddy, et al.
Published: (2022)

Fármacos recentes usados para o tratamento da infecção pelo HIV-1: enfuvirtida, maraviroc, raltegravir e etravirina
by: M.A. Brito
Published: (2011)

Post-mortem analysis of HIV-1 reservoir after allogeneic transplantation using stem cells
by: M. Nijhuis, et al.
Published: (2015)

32 Plasmacytoid DCs control HIV latency in resting T cells by type I IFNα
by: R.M. Van der Sluis, et al.
Published: (2017)

26 A novel assay to evaluate the response of patient-derived virus to latency-reversing agents ex vivo
by: H. Lu, et al.
Published: (2016)

Allogeneic stem cell transplantation in HIV-1 infected individuals
by: A.M.J. Wensing, et al.
Published: (2015)

HIV latency reversal using designed PKC modulators
by: M.D. Marsden, et al.
Published: (2017)

PP 3.8 - 00137 Characterization of the HIV-1 subtype C reservoir during ART in South-African men and women
by: N. Buchholtz, et al.
Published: (2022)

CCR9 Antagonists in the Treatment of Ulcerative Colitis
by: Pirow Bekker, et al.
Published: (2015)

No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV infected patients receiving suppressive maraviroc therapy
by: J. Izopet, et al.
Published: (2015)

Optimisation of Smac mimetics as HIV-1 latency reversing agents
by: L. Pache, et al.
Published: (2019)

Combinatorial latency reversal activity of inhibitor of apoptosis antagonists with mechanistically distinct classes of HIV latency reversal agents
by: Shane D. Falcinelli, et al.
Published: (2019)

24 Thalidomide reverses latency of HIV-1 provirus
by: S. Samer, et al.
Published: (2016)

Galectin-1 promotes HIV-1 latency reactivation
by: J. Rubione, et al.
Published: (2019)

In-depth transcription profile comparison of multiple primary cell HIV latency models
by: S. Moron-Lopez, et al.
Published: (2019)

50LB Central nervous system impact of vorinostat, hydroxychloroquine and maraviroc combination therapy followed by treatment interruption in individuals treated during acute HIV infection
by: E. Kroon, et al.
Published: (2016)

Induction of HIV from latency by a novel molecule
by: N.M. Archin, et al.
Published: (2015)

Influence of sex as an intrinsic biological variable in a primary cell model of HIV latency
by: A.B. Macedo, et al.
Published: (2017)

20 Sirtuin1 inhibitor nicotinamide disrupts HIV-1 latency
by: S. Samer, et al.
Published: (2016)

Characterization of humanized NSG mice to evaluate latency
by: S. Satheesan, et al.
Published: (2015)

Monitores de Frequência Cardíaca
by: Fernando A.M.J. Pompeu
Published: (2020)

OP 1.7 - 00194 Potent latency reversal enables in-depth transcriptomic analysis of the translation-competent HIV-1 reservoir
by: M. Pardons, et al.
Published: (2022)

Gut and blood differ in mechanisms governing HIV transcription/latency
by: S. Telwatte, et al.
Published: (2017)

Developing and applying ultrasensitive p24 protein immunoassay for HIV latency
by: B.J. Howell, et al.
Published: (2015)

A theoretical framework to guide clinical trial design to estimate efficacies of latency-reversing agents
by: R. Ke, et al.
Published: (2015)

Herpesvirus Latency
Published: (2020)

Expression of CCR3 and CCR4 Suggests a Poor Prognosis in Mycosis Fungoides and Sézary Syndrome
by: Yuki Shono, et al.
Published: (2019)